UroGen Pharma
NASDAQ: URGNPrinceton, US · Israel corporation · 2 known investors
A US-headquartered biotech company developing innovative solutions for urothelial and specialty cancers using RTGel hydrogel technology (exited July 2025).
Biotech
Founders & leadership
SH
Stuart Holden, M.D.Director
JS
Jason SmithExecutive Officer
AB
Arie Belldegrun, M.D.Director
DW
Dan WildmanDirector
FC
Fred Cohen, M.D.Director
DK
Don KimExecutive Officer
JA
James A. Robinson, Jr.Director
CB
Cynthia ButittaDirector
RN
Ran NussbaumDirector
EB
Elizabeth BarrettExecutive Officer, Director
LW
Leana Wen, M.D., MScDirector
MS
Mark Schoenberg, M.D.Executive Officer
Investors · 2
Reported raises · per SEC filings
Form D private placements▶$120MraisedAug 2023 · 8 investors · PharmaceuticalsRule 506(b)
▶$120MraisedAug 2023 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Stuart Holden, M.D.Director
- Jason SmithExecutive Officer
- Arie Belldegrun, M.D.Director
- Dan WildmanDirector
- Fred Cohen, M.D.Director
- Don KimExecutive Officer
- James A. Robinson, Jr.Director
- Cynthia ButittaDirector
- Ran NussbaumDirector
- Elizabeth BarrettExecutive Officer, Director
- Leana Wen, M.D., MScDirector
- Mark Schoenberg, M.D.Executive Officer
- Offering amount
- $120M
- Amount sold
- $120M
- Sales commissions
- $3.2M
- Placement agents
- H.C. Wainwright & Co., LLC, BofA Securities, Inc.
- First sale
- Jul 2023
- Incorporated
- Corporation, Israel
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.